ANEB vs. STSA, SLGL, TNXP, OPNT, OPTN, ELYM, GTHX, OVID, SBTX, and CDT
Should you be buying Anebulo Pharmaceuticals stock or one of its competitors? The main competitors of Anebulo Pharmaceuticals include Satsuma Pharmaceuticals (STSA), Sol-Gel Technologies (SLGL), Tonix Pharmaceuticals (TNXP), Opiant Pharmaceuticals (OPNT), OptiNose (OPTN), Eliem Therapeutics (ELYM), G1 Therapeutics (GTHX), Ovid Therapeutics (OVID), Silverback Therapeutics (SBTX), and Conduit Pharmaceuticals (CDT). These companies are all part of the "medical" sector.
Anebulo Pharmaceuticals (NASDAQ:ANEB) and Satsuma Pharmaceuticals (NASDAQ:STSA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, community ranking, profitability, institutional ownership, analyst recommendations, earnings and valuation.
Anebulo Pharmaceuticals presently has a consensus target price of $6.67, indicating a potential upside of 220.51%. Given Anebulo Pharmaceuticals' higher possible upside, research analysts plainly believe Anebulo Pharmaceuticals is more favorable than Satsuma Pharmaceuticals.
In the previous week, Anebulo Pharmaceuticals had 3 more articles in the media than Satsuma Pharmaceuticals. MarketBeat recorded 3 mentions for Anebulo Pharmaceuticals and 0 mentions for Satsuma Pharmaceuticals. Anebulo Pharmaceuticals' average media sentiment score of 1.88 beat Satsuma Pharmaceuticals' score of 0.00 indicating that Anebulo Pharmaceuticals is being referred to more favorably in the media.
28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. Comparatively, 93.3% of Satsuma Pharmaceuticals shares are held by institutional investors. 85.9% of Anebulo Pharmaceuticals shares are held by company insiders. Comparatively, 31.2% of Satsuma Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Satsuma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Satsuma Pharmaceuticals' return on equity of -115.24% beat Anebulo Pharmaceuticals' return on equity.
Anebulo Pharmaceuticals has a beta of -0.98, indicating that its stock price is 198% less volatile than the S&P 500. Comparatively, Satsuma Pharmaceuticals has a beta of 0.1, indicating that its stock price is 90% less volatile than the S&P 500.
Satsuma Pharmaceuticals received 224 more outperform votes than Anebulo Pharmaceuticals when rated by MarketBeat users. However, 87.50% of users gave Anebulo Pharmaceuticals an outperform vote while only 63.46% of users gave Satsuma Pharmaceuticals an outperform vote.
Summary
Anebulo Pharmaceuticals beats Satsuma Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
Get Anebulo Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANEB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANEB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Anebulo Pharmaceuticals Competitors List
Related Companies and Tools
